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Abstract
In recent years, many important discoveries have been made to challenge current
policy,guidelines,andpracticeregardinghowbesttopreventstrokeassociatedwith
atheroscleroticstenosisoftheoriginoftheinternalcarotidartery.TheUnitedStates
CenterforMedicareandMedicaidServices(CMS),forinstance,iscallingforexpert
advice as to whether its current policies should be modiﬁed. Using a thorough
review of literature, 41 leading academic stroke-prevention clinicians from the
UnitedStatesand othercountries,have unitedto advise CMS not to extendcurrent
reimbursement indications for carotid angioplasty/stenting (CAS) to patients with
asymptomatic carotid stenosis or to patients with symptomatic carotid stenosis
considered to be at “low or standard risk from carotid endarterectomy (CEA).”
It was concluded that such expansion of reimbursement indications would have
disastrous health and economic consequences for the United States and any other
country that may follow such inappropriateaction. This wasan internationaleffort
because the experts to best advise CMS are relatively few and scattered around the
world. In addition, US health policy, practice, and research have tended to have
strong inﬂuences on other countries.
A potential crisis looms in the United States–related to the
proposal for the US Center for Medicare and Medicaid Ser-
vices (CMS) to allow wider indications for government re-
imbursement for carotid angioplasty/stenting (CAS). We are
writing to advise CMS to reject this proposal based on over-
whelmingevidencethatitwouldhaveseriousnegativehealth
and economic repercussions for the United States and any
other country that may follow such inappropriate action.
The purpose of this message is not to advise on existing
CMS policy. Instead, we wish to advise that current Medi-
care coverage for CAS should not be extended to routine
practice management of asymptomatic carotid stenosis or
symptomatic carotid stenosis where the patient is consid-
ered at “low/average risk” of complications from carotid en-
darterectomy (CEA). We understand that, currently, CMS
c o v e r st h ec o s to fC A Sf o rt h ei n d i c a t i o n sl i s t e db e l o w( t h e
National Coverage Determination [NCD] for Percutaneous
Transluminal Angioplasty [PTA] March 05, 2010):
(1) Concurrentwithcarotidstentplacementwhenfurnished
in accordance with the FDA-approved protocols governing
Category B Investigational Device Exemption (IDE) clinical
trials.
(2) Concurrent with the placement of an FDA-approved
carotid stent and an FDA-approved or -cleared embolic pro-
tection device for an FDA-approved indication when fur-
nished in accordance with FDA-approved protocols govern-
ing postapproval studies.
(3) Concurrent with the placement of an FDA-approved
carotidstentwithanFDA-approvedor-clearedembolicpro-
tection device for the patients who are at high risk for CEA
and who also have symptomatic carotid artery stenosis more
than 70%.
(4) Patients who are at high risk for CEA and have symp-
tomaticcarotidarterystenosisof50–70%,inaccordancewith
the Category B IDE clinical trials or in accordance with the
NCD on carotid artery stenting postapproval studies.
(5) Patients who are at high risk for CEA and have asymp-
tomaticcarotidarterystenosismorethan80%,inaccordance
with theCategoryBIDEclinicaltrialsregulationorinaccor-
dance with the NCD on CAS postapproval studies.
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According to the same NCD, patients at high risk for
CEA are deﬁned as having signiﬁcant comorbidities and/or
anatomicriskfactors(i.e.,recurrentstenosisand/orprevious
radical neck dissection), so that they would be considered
poor candidates for CEA. Signiﬁcant comorbid conditions
include but are not limited to the following:
(1) Congestive heart failure (CHF) class III/IV;
(2) Left ventricular ejection fraction (LVEF) < 30%;
(3) Unstable angina;
(4) Contralateral carotid occlusion;
(5) Recent myocardial infarction (MI);
(6) Previous CEA with recurrent stenosis;
(7) Prior radiation treatment to the neck; and
(8) Otherconditionsthatwereusedtodeterminepatientsat
highriskforCEAinthepriorcarotidarterystentingtrialsand
studies,suchasARCHER,CABERNET,SAPPHIRE,BEACH,
and MAVERIC II.
Over the last two to three years the available evidence to
directcurrentbeststroke-preventionmanagementofcarotid
stenosis has been reviewed by a number of leading academic
clinicians. Current routine practice management of carotid
stenosis is based on results of randomized trials of medi-
cal (noninvasive) intervention alone versus additional CEA
for patients with symptomatic (Mayberg et al. 1991; North
American Symptomatic Carotid Endarterectomy Trial Col-
laborators1991;TheEuropeanCarotidSurgeryTrialistsCol-
laborative Group 1998) or asymptomatic (Hobson et al.
1993; Executive Committee for the Asymptomatic Carotid
AtherosclerosisStudy1995;Hallidayetal.2004;2010)carotid
stenosis. In these trials patients were randomized up to 30
years ago (1981–1994 and 1983–2003, respectively). Overall,
an average annual stroke-prevention beneﬁt of about 3.0%
was measured for operated patients with moderate or severe
(70–99% NASCET equivalent) symptomatic (Rerkasem and
Rothwell 2011) carotid stenosis and about 0.5–1% for oper-
ated patients with moderate or severe (50–99% NASCET
equivalent) asymptomatic (Chambers and Donnan 2005;
Halliday et al. 2010) carotid stenosis compared to patients
who received medical intervention alone. More recently, tri-
alsofCASversusCEA(withoutamedicalintervention-only-
arm) were performed demonstrating that the perioperative
stroke risk is twice about as high with stenting when com-
pared with CEA (see below). These trials were most likely
designed assuming medical intervention has not changed
sincetherandomizedsurgicaltrials,aimingtoﬁndatleastan
equivalentCEAstroke-preventionbeneﬁt.However,itisnow
clear that the stroke-prevention efﬁcacy of medical interven-
tion has steadily and signiﬁcantly improved over the last 30
years and continues to improve (Abbott 2009; Naylor et al.
2009; Abbott 2010; Naylor 2011; Spence et al. 2010), consis-
tentwithotherobservedfallsinriskofstroke (Rothwelletal.
2004; Broderick 2011; Chimowitz et al. 2011), heart attack,
and sudden death (Unal et al. 2005). Currently used bench-
marksforastroke-preventionbeneﬁtfromCEAovermedical
intervention (a 30-day procedural risk of stroke/death of 3%
for asymptomatic carotid stenosis [Goldstein et al. 2011] or
6% for symptomatic carotid stenosis [Furie et al. 2011]) are
outdated.Therefore,thedemonstrationofstroke-prevention
equivalence between CAS and CEA using these benchmarks
(even if this had been achieved) would be insufﬁcient to jus-
tify a current, routine practice indication for CAS.
The inappropriateness of the recent push for widening
CMScoverageforcarotidstentingisparticularlyevidentwith
respect to asymptomatic carotid stenosis because the ran-
domized surgical trial stroke-prevention beneﬁt from CEA
wassosmallandconditional.However,themostrecentstan-
dardized measurements of the average annual rate of ipsi-
lateral stroke among patients receiving medical intervention
alone approximate only 0.5% (Goessens et al. 2007; Abbott
2010;Markusetal.2010;Marquardtetal.2010).Thisisabout
threetimes lower thanfor randomizedsurgicaltrial CEA pa-
tients (Executive Committee for the Asymptomatic Carotid
AtherosclerosisStudy1995),aboutﬁvetimeslowerthanran-
domizedsurgicaltrialnonoperatedpatients(ExecutiveCom-
mittee for the Asymptomatic Carotid Atherosclerosis Study
1995), three times lower than CREST stented patients (Brott
et al. 2010), and about half the rate of CREST CEA patients
(Abbott 2009, 2010; Brott et al. 2010). The push for routine
practice stenting for asymptomatic carotid stenosis is based
largely on the recently published CREST results (Brott et
al. 2010), and perhaps other clearly ﬂawed randomized data
(Brooks et al. 2004; Yadav et al. 2004), comparing CEA with
CAS (without a medical intervention-only-arm) and impli-
cations of “equivalence” with CEA (Brott et al. 2011). As
mentioned, such equivalence, even if supported by the data,
would not be sufﬁcient to justify a current, routine practice
indication for CAS for asymptomatic carotid stenosis.
However, to add insult to injury, an equivalent stroke-
prevention beneﬁt between CAS and CEA has not been
demonstrated. CAS in CREST (Brott et al. 2010), large reg-
istries, and population-based studies (Sidawy et al. 2009;
Giles et al. 2010; Rockman et al. 2011), has been associ-
ated with about double the peri-procedural rate of stroke or
death compared to CEA. Further, in CREST, among asymp-
tomatic patients, the rate of peri-procedural stroke/death or
later ipsilateral stroke projected to four years was 4.5% for
594patientswhohadCASand2.7%forthe587whohadCEA
(67% higher, P = 0.07). This outcome measure reached sta-
tistical signiﬁcance when symptomatic patients were added
(6.4% vs. 4.7%, 36% higher, P = 0.03). The inclusion of
higher risk symptomatic patients, and larger sample sizes,
allows easier detection of statistically signiﬁcant differences.
Supporters of routine CAS for asymptomatic carotid steno-
sis have tried to use a higher incidence of peri-procedural
myocardial infarction (including minor infarction) associ-
ated with CEA to justify a higher stroke/death risk with CAS
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(Blackshearetal.2011).However,thisisinvalidanddistract-
ingbecausetheaimofinvasivecarotidinterventionistopre-
ventstroke.Further,inCREST,atleast,alargerproportionof
patients who suffered peri-procedural myocardial infarction
associated with CAS (compared to CEA) died during follow-
up (Naylor 2012a). More importantly, procedure-associated
myocardial damage would be prevented entirely if unneces-
sary CEA and CAS interventions were not performed in the
ﬁrst place. In addition, it should also be noted that CAS has
higher procedural costs compared to CEA (Paraskevas et al.
2011b).
The current situation regarding CEA and CAS for patients
withasymptomaticstenosisintheUnitedStatesisunjustiﬁed
and outdated. Up to about 90–95% of these procedures are
being performed for asymptomatic carotid stenosis (Hertzer
2011; Rockman et al. 2011), exposing patients to unneces-
sary risk and causing unjustiﬁed expenditure of at least one
to two billion US health care dollars each year (Abbott 2009;
Naylor et al., 2009; Hankey 2010; Bell 2011; Naylor 2012b;
SpenceandVeith2011)atatimewhenhealthcarecostsneed
to be justiﬁed (Redberg 2011). Despite no previous CMS
coverage for routine practice CAS for asymptomatic carotid
stenosis,ratesofCASproceduresareincreasingdramatically,
especiallyamongcardiologists(BerkowitzandRedberg2011;
Nallamothu et al. 2011). Extending the approved indications
for CAS will open the ﬂoodgates for widespread CAS and
expose patients to unnecessary risk and greatly increase un-
justiﬁed health expenditure (Paraskevas et al. 2011b).
Broadening the indications for CAS reimbursement for
symptomatic carotid stenosis is also inappropriate. The re-
quest for such broadening of reimbursement will, once
again, be based on the CREST trial conclusions (Brott et al.
2010) and the recently published American Heart Associa-
tion (AHA) Guideline (approved by 13 other organizations)
(Brott et al. 2011), which states that “CAS is an alternative to
CEA for the treatment of symptomatic carotid stenosis...”
Equivalence of the two procedures is implied (Paraskevas
et al. 2011c, d). Unfortunately, the actual CREST data
(Silver et al. 2011), most other randomized trial data (Mas
et al. 2006, 2008; Ederle et al. 2010), meta-analyses (Bonati
et al. 2010a; Economopoulos et al. 2011), and registry data
(Sidawy et al. 2009; Giles et al. 2010; Rockman et al. 2011)
donotjustifythispresumedequivalenceofCASandCEAfor
symptomatic carotid stenosis (Carotid Stenting Guidelines
Committee 2011; Paraskevas et al. 2011a). In symptomatic
p a t i e n t s ,C A S ,o v e r a l l ,i sa s s o c i a t e dw i t ha b o u td o u b l et h e
30-day, 120-day, 6-month, and/or 4-year risk of stroke (or
death) compared to CEA. The excessive CAS procedural risk
of stroke or death is particularly notable in patients over 70
years of age (Bonati and Fraedrich 2011), yet not conﬁned to
theoldestagegroups(Silveretal.2011).CASisalsoassociated
withamuchhigherperi-proceduralriskofbrain-imagingde-
tected ischemic lesions than CEA (Bonati et al. 2010b) and
a higher incidence of carotid restenosis (Eckstein et al. 2008;
Bonati et al. 2009; Arquizan et al. 2011). No studies have
shown CAS is better than CEA in preventing stroke in pa-
tientswithsymptomaticcarotidstenosisandproceduralcosts
are signiﬁcantly higher with CAS (Paraskevas et al. 2011b).
Thus, the extension of Medicare reimbursement to routine
treatment for “low” and “standard” CEA-risk patients with
symptomatic carotid stenosis is not currently justiﬁed.
Thus,insummary,atthistime,theevidencedoesnotsup-
portbroadeningreimbursementforCAStoroutinemanage-
ment of patients with asymptomatic carotid stenosis or pa-
tients with symptomatic carotid stenosis considered at “low
or standard” risk from CEA. It is acknowledged that this
situation may change in the future.
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